Drug intelligence / Profile preview

CLB-3000

Development stage
Phase 1
Lead developer
ClearB Therapeutics
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

**CLB-3000** is an investigational bivalent protein-subunit therapeutic vaccine from ClearB Therapeutics for chronic hepatitis B infection. It contains two proprietary engineered hepatitis B surface antigen variants, CLB-405 and CLB-505, designed to over-represent viral clearance-associated epitopes identified in individuals with functional cure, and is adjuvanted with Alhydrogel. The vaccine is intended to redirect or strengthen HBV-specific immune responses to promote functional cure, including reduction or clearance of hepatitis B surface antigen. CLB-3000 is being evaluated in an open-label Phase 1b study in adults with chronic hepatitis B receiving stable nucleoside or nucleotide analogue therapy. ([clearbtherapeutics.com](https://clearbtherapeutics.com/1313-2/))

Other names
CLB-405 + CLB-505 with Alhydrogel
02

Targets

HBsAg-specific BCR (HBsAg-specific B-cell receptor)Hepatitis B surface antigen-specific T-cell receptorHBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on CLB-3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLB-3000.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call